Literature DB >> 21076602

Is Chemoendocrine Treatment without Alternative?

Richard Greil1.   

Abstract

Year:  2008        PMID： 21076602      PMCID： PMC2974977          DOI： 10.1159/000149558

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  40 in total

1.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

Authors:  Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang
Journal:  Lancet       Date:  2005 Aug 6-12       Impact factor: 79.321

2.  Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

Authors:  Nancy E Davidson; Anne M O'Neill; Allen M Vukov; C Kent Osborne; Silvana Martino; Douglas R White; Martin D Abeloff
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

3.  Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.

Authors:  C Mayers; T Panzarella; I F Tannock
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

4.  Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.

Authors: 
Journal:  J Natl Cancer Inst       Date:  2007-04-04       Impact factor: 13.506

5.  CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).

Authors:  Gunter von Minckwitz; Erika Graf; Matthias Geberth; Wolfgang Eiermann; Walter Jonat; Bettina Conrad; Klaus Brunnert; Bernd Gerber; Sabine Vescia; Jörg Wollert; Manfred Kaufmann
Journal:  Eur J Cancer       Date:  2006-06-12       Impact factor: 9.162

6.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors:  Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

7.  Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.

Authors:  Debra A Patt; Zhigang Duan; Shenying Fang; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2007-07-30       Impact factor: 44.544

8.  Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.

Authors:  Fabrice Andre; Kristine Broglio; Henri Roche; Miguel Martin; John R Mackey; Frederique Penault-Llorca; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

Review 9.  Commercialized multigene predictors of clinical outcome for breast cancer.

Authors:  Jeffrey S Ross; Christos Hatzis; W Fraser Symmans; Lajos Pusztai; Gabriel N Hortobágyi
Journal:  Oncologist       Date:  2008-05

10.  A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast.

Authors:  T Korhonen; H Huhtala; K Holli
Journal:  Breast Cancer Res Treat       Date:  2004-05       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.